Coulter Bexxar
Executive Summary
New NDA filing for the iodine I 131 tositumomab product is no longer expected by mid-October, CEO Michael Bigham told analysts Sept. 28. The Aug. 27 "refuse-to-file" letter from FDA required Coulter to reformat selected data sets, reorganize certain analyses and provide archival images. Bigham said a meeting the company requested with FDA will not take place until mid-October, delaying the resubmission. Co-marketing partner SmithKline Beecham has indicated that it is helping Coulter with the submission (1"The Pink Sheet" Sept. 27, p. 22)
You may also be interested in...
Corixa Acquisition Of Coulter Gives Company Bexxar, Pending At FDA
Corixa's acquisition of Coulter will give the company its most advanced late-stage clinical product, the non-Hodgkin's lymphoma therapy Bexxar.
Corixa Acquisition Of Coulter Gives Company Bexxar, Pending At FDA
Corixa's acquisition of Coulter will give the company its most advanced late-stage clinical product, the non-Hodgkin's lymphoma therapy Bexxar.
Zevalin/Rituxan Has 80% Response Rate In Non-Hodgkin's Lymphoma Patients
Idec's mouse monoclonal antibody Zevalin in combination with the firm's Rituxan produced an 80% overall response rate in patients with relapsed B-cell non-Hodgkin's lymphoma in an interim analysis of Phase III data presented in a poster May 23 at the American Society for Clinical Oncology annual meeting in New Orleans.